Ceribell, Inc. (CBLL) AI Stock Analysis

• Market Cap: $673.34M
• Dividend Yield: N/A
• Average Volume (3M): 362.37K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.88
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 281
• Sector: Healthcare
• Sector Strength: 39
• Industry: Medical - Devices
• EPS (TTM): -0.36
• Shares Outstanding: 36,143,020
• 10 Day Avg. Volume: 482,038
• 30 Day Avg. Volume: 362,372
• PEG Ratio: 0.00
• Price to Book (P/B): -6.75
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -17.93
• Enterprise Value/Market Cap: 0.79
• Enterprise Value/Revenue: 2.74
• Enterprise Value/Gross Profit: 8.60
• Enterprise Value/Ebitda: -4.78
• 1Y Price Target: $31.40
• Price Target Upside: 68.55% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6

• Rating: 59 Neutral
• Price Target: $18.50 ▼(-0.70%Downside)

Ceribell, Inc. receives a moderate score of 59. The company's robust revenue growth and strategic advancements are tempered by significant profitability challenges and cash management issues. Technical indicators favor short-term momentum, but the lack of valuation clarity and increased expenses present risks.

Positive Factors

Financial Performance

Ceribell has reported full-year gross margins of approximately 87% and total revenue of $65.4 million, representing a 45% year-over-year growth.

Market Expansion

The company's pipeline includes initiatives like recent label expansion into pediatrics and plans for extension into neonates and new indications, which are expected to expand its Total Addressable Market.

Revenue Growth

Ceribell's sales of $20.5 million surpassed estimates, driven by new account acquisitions and strong utilization in existing accounts.

Negative Factors

External Factors

Ceribell's fundamentals remain strong despite recent stock pressure from external factors such as China tariffs and lock-up expiration.

Geopolitical Risk

Ceribell faces geopolitical risk with its China-based manufacturing operations, which could impact gross margins due to potential tariff changes.

Stock Pressure

The stock has fallen 35% largely due to exposure to China manufacturing and lock-up expiration.

Ceribell, Inc. Business Overview & Revenue Model

Company Description

Ceribell, Inc. (CBLL) is a medical technology company that specializes in developing and providing rapid electroencephalography (EEG) solutions for the diagnosis and management of neurological conditions. The company focuses on creating innovative, user-friendly EEG systems that improve the speed and accuracy of diagnosing conditions such as seizures in emergency and critical care settings. Ceribell's core product is the Ceribell EEG system, designed to be portable and easy to use, enabling healthcare professionals to rapidly conduct EEGs at the point of care.

How the Company Makes Money

Ceribell, Inc. generates revenue primarily through the sale of its EEG systems to hospitals and medical institutions. The company's revenue model includes the direct sale of its EEG hardware, as well as recurring revenue from the consumables and accessories required for the operation of these systems. Additionally, Ceribell may offer service contracts and training for healthcare providers to ensure proper usage and maintenance of their equipment. Significant partnerships with hospitals, healthcare systems, and potentially government health bodies could contribute to the company's earnings by facilitating broader adoption of their technology.

Ceribell, Inc. Financial Statement Overview

Summary

Ceribell, Inc. demonstrates strong revenue growth and improved equity, suggesting financial stability. However, negative net profit margins, high operating expenses, and reliance on external financing reveal significant profitability and cash management challenges.

Income Statement

Ceribell, Inc. shows solid revenue growth of 44.7% from 2023 to 2024, highlighting strong demand for their products. However, the company is operating at a loss with a negative net profit margin, and EBIT and EBITDA margins indicate inefficiencies. Gross profit margins are strong at approximately 86.7% for 2024, signifying good production cost management but are overshadowed by the high operating expenses.

Balance Sheet

The company's equity has significantly improved from negative to a strong positive position in 2024, indicating strong financial backing or recent capital infusion. The debt-to-equity ratio is low due to high equity, showcasing low leverage risk. However, the equity ratio is high at 84.8%, reflecting a stable asset base primarily funded by equity.

Cash Flow

Ceribell's free cash flow is negative but has shown improvement from 2023. The high operating cash outflows are concerning, relative to the negative net income, indicating cash management issues. A significant financing cash flow in 2024 suggests reliance on external funding to cover operational deficits.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	71.08M	65.44M	45.23M	25.92M
Gross Profit	62.01M	56.75M	38.16M	21.49M
EBITDA	-43.74M	-37.71M	-26.51M	-35.06M
Net Income	-44.50M	-40.45M	-29.46M	-37.16M
Balance Sheet
Total Assets	213.47M	225.41M	58.92M	86.46M
Cash, Cash Equivalents and Short-Term Investments	182.70M	194.37M	34.49M	68.23M
Total Debt	21.76M	21.96M	14.20M	18.22M
Total Liabilities	20.76M	34.25M	171.17M	172.86M
Stockholders Equity	180.88M	191.16M	-112.25M	-86.40M
Cash Flow
Free Cash Flow	-39.90M	-36.38M	-30.14M	-32.52M
Operating Cash Flow	-38.18M	-35.04M	-29.16M	-32.00M
Investing Cash Flow	-30.56M	-1.60M	-1.76M	-1.40M
Financing Cash Flow	192.68M	196.52M	-2.82M	49.80M

Ceribell, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IRMD	81 Outperform	$782.49M	39.79	23.81%	1.10%	11.04%	9.84%
CBLL	59 Neutral	$673.34M	―	26.25%	―	―	―
AXGN	59 Neutral	$503.72M	―	-7.22%	―	18.81%	67.41%
Sector *	52 Neutral	$7.50B	0.31	-61.87%	2.27%	17.10%	1.59%
AVNS	48 Neutral	$572.50M	45.80	-36.78%	―	1.34%	-530.36%
BFLY	47 Neutral	$479.74M	―	-29.16%	―	25.77%	49.44%
RXST	45 Neutral	$533.97M	―	-11.98%	―	46.69%	46.68%

Ceribell, Inc. Corporate Events

Ceribell Extends Exclusive License with Stanford University

Ceribell, Inc. and Stanford University have amended their exclusive agreement, initially effective from June 15, 2015, to extend the exclusivity of Ceribell’s license for certain portable brain wave activity devices. On June 12, 2025, Ceribell exercised an option to extend this exclusivity by paying a $250,000 fee, which impacts the company’s operations by securing continued access to patented technology.

The most recent analyst rating on (CBLL) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Ceribell, Inc. stock, see the CBLL Stock Forecast page.

Ceribell, Inc. Announces Results of Annual Meeting

On June 10, 2025, Ceribell, Inc. held its Annual Meeting of Stockholders, where two key proposals were voted on. The stockholders elected Juliet Tammenoms Bakker and Lucian Iancovici, M.D. as Class I directors to serve until the 2028 meeting, and approved the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (CBLL) stock is a Buy with a $31.00 price target. To see the full list of analyst forecasts on Ceribell, Inc. stock, see the CBLL Stock Forecast page.

Ceribell, Inc. Addresses Impact of New U.S. Tariffs

Ceribell, Inc. has addressed the potential impact of newly announced U.S. tariffs on goods imported from China, which affect the company’s headband product manufactured by Chinese contractors. The company anticipates no significant financial impact from these tariffs until the fourth quarter of 2025 due to existing inventory, but expects an 8 to 10 percentage point reduction in gross margins once current inventory is depleted. The tariffs are not expected to affect the cost of revenue from subscription products.